Introduction Repare Therapeutics is a firm that develops cancer drugs, aiming to exploit the distinct weaknesses of tumor cells. Their proprietary high throughput gene-editing and target discovery process coupled with high-resolution protein crystallography, computational biology, and clinical informatics are incorporated into their pharmaceuticals. It was founded in 2016 by a group of experienced oncology professionals, including Lloyd Segal and Daniel Durocher, with the intention to develop various oncology drugs. |
Disease Domain | Count |
---|---|
Neoplasms | 5 |
Immune System Diseases | 1 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Unknown | 1 |
Target |
Mechanism PKMYT1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ATR inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PLK4 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date14 Feb 2024 |
Sponsor / Collaborator |
Start Date24 May 2023 |
Sponsor / Collaborator |
Start Date30 Sep 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Camonsertib ( ATR ) | Endometrial Carcinoma More | Phase 2 Clinical |
Lunresertib ( PKMYT1 ) | Endometrial Carcinoma More | Phase 2 |
RP-1664 ( PLK4 ) | Neuroblastoma More | Preclinical |
RP-2119 ( POLQ ) | Neoplasms More | Preclinical |
RP-3467 ( POLQ ) | Neoplasms More | Preclinical |